Talphera (NASDAQ:TLPH) Upgraded by Maxim Group to “Strong-Buy” Rating

Maxim Group upgraded shares of Talphera (NASDAQ:TLPH) to a strong-buy rating in a research report sent to investors on Friday,Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Talphera in a research report on Friday, August 16th.

Talphera Stock Performance

NASDAQ:TLPH opened at $0.89 on Friday. Talphera has a one year low of $0.43 and a one year high of $1.61. The firm has a market cap of $15.12 million, a price-to-earnings ratio of -1.39 and a beta of 0.31. The firm’s fifty day moving average is $0.90 and its two-hundred day moving average is $0.94.

Talphera (NASDAQ:TLPH) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.07. As a group, equities research analysts predict that Talphera will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Rosalind Advisors Inc. purchased a new stake in shares of Talphera in the third quarter valued at about $650,000. Nantahala Capital Management LLC purchased a new stake in shares of Talphera in the second quarter valued at about $1,773,000. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in shares of Talphera in the second quarter valued at approximately $64,000. 37.67% of the stock is currently owned by institutional investors and hedge funds.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.